By Bhanvi Satija (Reuters) -Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...